Targeting EGFR in lung cancer: Lessons learned and future perspectives.

  title={Targeting EGFR in lung cancer: Lessons learned and future perspectives.},
  author={Conor E. Steuer and Suresh S Ramalingam},
  journal={Molecular aspects of medicine},
The development of individualized therapies has become the focus of current oncology research. Precision medicine has demonstrated great potential for bringing safe and effective drugs to those patients stricken with cancer, and is becoming a reality as more oncogenic drivers of malignancy are discovered. The discovery of Epidermal Growth Factor Receptor (EGFR) mutations as a driving mutation in non-small cell lung cancer (NSCLC) and the subsequent success of the tyrosine kinase inhibitors (TKI… CONTINUE READING
Highly Cited
This paper has 40 citations. REVIEW CITATIONS
Recent Discussions
This paper has been referenced on Twitter 2 times over the past 90 days. VIEW TWEETS


Publications citing this paper.
Showing 1-10 of 18 extracted citations


Publications referenced by this paper.
Showing 1-10 of 61 references

Continuation of Gefitinib Plus Pemetrexed/Cisplatin of No Clinical Benefit in NSCLC Patients with Acquired Resistance to Gefitinib

  • T. Mok, Y. L. Wu, K Nakagawa
  • 2014
Highly Influential
1 Excerpt

Safety and Response with Nivolumab (anti-PD-1; BMS-936558, ONO-4538) Plus Erlotinib in Patients (pts) with Epidermal Growth Factor Receptor Mutant (EGFR MT) Advanced NSCLC

  • N. A. Rizvi, L. Chow, H Borghaei
  • 2014
Highly Influential
2 Excerpts

Updated safety and efficacy from a Phase I study of AZD9291 in patients with EGFR-TKI-resistant non-small cell lung cancer (NSCLC). European Society for Medical Oncology (ESMO

  • C. H. Yang, D. W. Kim, D Plachard
  • 2014
Highly Influential
1 Excerpt

Similar Papers

Loading similar papers…